<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03540446</url>
  </required_header>
  <id_info>
    <org_study_id>FRT-PN-18</org_study_id>
    <nct_id>NCT03540446</nct_id>
  </id_info>
  <brief_title>First Relief Treatment for Peripheral Neuropathy</brief_title>
  <acronym>FRT-PN</acronym>
  <official_title>To Prove the Effectiveness of PENS Therapy With Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DyAnsys, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DyAnsys, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To prove the effectiveness of Percutaneous Electrical Neuro-stimulation therapy for the
      treatment of conditions associated with peripheral neuropathy, in a double-blind environment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 4, 2018</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Actual">September 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of Neuropathy pain</measure>
    <time_frame>According to the patients condition and other factors expected to reduce pain in 4th week of the treatment</time_frame>
    <description>This treatments effective outcome will be, &quot;Percutaneous Electrical Nerve Stimulation therapy will have the ability to reduce the pain and other conditions regarding peripheral neuropathy&quot; which can be verified through &quot;Biothesiometer&quot; parameters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Check for delay of Re-occurrence of pain within a short time</measure>
    <time_frame>90 Days</time_frame>
    <description>After the treatment of 4th week the pain will be reduced and the treatment is continued for other 3 weeks where the booster dose is applied for the assurance of delay of pain which is evaluated manually by the medical personals after 90 days of booster dose treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Complete reduction of conditions associated with peripheral neuropathy</measure>
    <time_frame>7 weeks</time_frame>
    <description>After the overall treatment has been completed the conditions associated with peripheral neuropathy will be completely reduced and the occurrence of the pain will be stopped which can be verified and evaluated through &quot;Biothesiometer&quot; parameters.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Standard stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A will be treated with First Relief Treatment at standard stimulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sweep stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B will be treated with First Relief Treatment at sweep stimulation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group C will be treated with First Relief Treatment, receiving a placebo.(dummy device with no electrical stimulation)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>First Relief Treatment</intervention_name>
    <description>To prove the effectiveness of Percutaneous Electrical Neuro-stimulation therapy for the treatment of conditions associated with peripheral neuropathy, in a double-blind environment.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Standard stimulation</arm_group_label>
    <arm_group_label>sweep stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Neuropathy pain

        Exclusion Criteria:

          -  Patient with inbuilt pacemakers or any other devices which allows current into the
             body, pregnant ladies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Gurunath, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Jeevak hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic</name>
      <address>
        <city>Warangal</city>
        <state>Telangana</state>
        <zip>506002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>April 24, 2018</study_first_submitted>
  <study_first_submitted_qc>May 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2018</study_first_posted>
  <last_update_submitted>September 20, 2018</last_update_submitted>
  <last_update_submitted_qc>September 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First Relief</keyword>
  <keyword>Diebetes</keyword>
  <keyword>Pheripheral Neuropathy</keyword>
  <keyword>Pain Releif</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

